Cefiderocol

Phase 1Completed

0 views this week 0 watching💤 Quiet

Interest: 29/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Sepsis

Conditions

Sepsis

Trial Timeline

Jul 16, 2021 → Sep 1, 2024

NCT ID

NCT04995835

About Cefiderocol

Cefiderocol is a phase 1 stage product being developed by Shionogi for Sepsis. The current trial status is completed. This product is registered under clinical trial identifier NCT04995835. Target conditions include Sepsis.

What happened to similar drugs?

9 of 19 similar drugs in Sepsis were approved

Approved (9) Terminated (1) Active (9)

✅MeropenemPfizerApproved

✅ImipenemMerckApproved

✅Drotrecogin Alfa (activated)Eli LillyApproved

✅Drotrecogin alfa (activated)Eli LillyApproved

✅Drotrecogin Alfa (Activated) + Unfractionated heparin + Low molecular weight heparinEli LillyApproved

✅drotrecogin alfa (activated)Eli LillyApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (7)

NCT ID	Phase	Status	Start	Completion	Indication
NCT03780140	Pre-clinical	Completed	—	—	Bacterial Infections
NCT07465432	Approved	Recruiting	Feb 16, 2026	Feb 28, 2027	Drug Clearance After Severe Burn Injury
NCT05789199	Pre-clinical	Completed	Jul 31, 2022	Jun 16, 2023	Gram-Negative Infection
NCT05373615	Phase 1	Completed	Jul 25, 2022	Nov 20, 2024	Pharmacokinetics
NCT05314764	Approved	Completed	Jun 1, 2022	Dec 11, 2024	Cystic Fibrosis
NCT04995835	Phase 1	Completed	Jul 16, 2021	Sep 1, 2024	Sepsis
NCT03869437	Phase 2	Completed	Oct 28, 2019	Jan 29, 2024	Bloodstream Infections

Competing Products

20 competing products in Sepsis

See all competitors

Product	Company	Stage	Hype Score
Alkaline Phosphatase + Placebo	AM-Pharma	Phase 2	25
Drotrecogin alfa (activated)	Eli Lilly	Phase 2	35
Meropenem	Pfizer	Approved	43
Imipenem	Merck	Approved	39
eritoran tetrasodium + Placebo	Eisai	Phase 3	40
E5564	Eisai	Phase 2	35
Drotrecogin Alfa (Activated) + placebo	Eli Lilly	Phase 3	40
Drotrecogin alfa (activated) + Placebo	Eli Lilly	Phase 3	40
Drotrecogin Alfa (activated)	Eli Lilly	Approved	43
Drotrecogin alfa (activated) + Placebo	Eli Lilly	Phase 3	40
Drotrecogin alfa (activated) + Placebo	Eli Lilly	Phase 3	40
sPLA2 Inhibitor	Eli Lilly	Phase 1/2	32
Drotrecogin alfa (activated)	Eli Lilly	Approved	43
Drotrecogin Alfa (Activated) + Unfractionated heparin + Low molecular weight heparin	Eli Lilly	Approved	43
drotrecogin alfa (activated)	Eli Lilly	Approved	43
drotrecogin alfa (activated)	Eli Lilly	Approved	43
AZD9773 (CytoFab)	AstraZeneca	Phase 2	35
AZD9773 + Placebo	AstraZeneca	Phase 2	35
AZD9773 + Placebo	AstraZeneca	Phase 2	35
AZD4144 + Placebo	AstraZeneca	Phase 2	42